Klinkhammer Barbara Mara, Boor Peter
Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.
Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany; Electron Microscopy Facility, RWTH Aachen University Hospital, Aachen, Germany; Division of Nephrology and Immunology, RWTH Aachen University Hospital, Aachen, Germany.
Mol Aspects Med. 2023 Oct;93:101206. doi: 10.1016/j.mam.2023.101206. Epub 2023 Aug 3.
An increasing number of patients worldwide suffers from chronic kidney disease (CKD). CKD is accompanied by kidney fibrosis, which affects all compartments of the kidney, i.e., the glomeruli, tubulointerstitium, and vasculature. Fibrosis is the best predictor of progression of kidney diseases. Currently, there is no specific anti-fibrotic therapy for kidney patients and invasive renal biopsy remains the only option for specific detection and quantification of kidney fibrosis. Here we review emerging diagnostic approaches and potential therapeutic options for fibrosis. We discuss how translational research could help to establish fibrosis-specific endpoints for clinical trials, leading to improved patient stratification and potentially companion diagnostics, and facilitating and optimizing development of novel anti-fibrotic therapies for kidney patients.
全球范围内，越来越多的患者患有慢性肾脏病（CKD）。CKD伴有肾纤维化，它会影响肾脏的所有部分，即肾小球、肾小管间质和血管系统。纤维化是肾脏疾病进展的最佳预测指标。目前，尚无针对肾病患者的特异性抗纤维化疗法，而侵入性肾活检仍是特异性检测和定量肾纤维化的唯一选择。在此，我们综述了针对纤维化的新兴诊断方法和潜在治疗选择。我们讨论了转化研究如何有助于为临床试验建立纤维化特异性终点，从而改善患者分层并可能实现伴随诊断，并促进和优化针对肾病患者的新型抗纤维化疗法的开发。
